Literature DB >> 6322583

Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients.

A H Rook, G V Quinnan, W J Frederick, J F Manischewitz, N Kirmani, T Dantzler, B B Lee, C B Currier.   

Abstract

Thirty renal transplant recipients were studied prospectively to evaluate the relationship of cytomegalovirus-specific cytotoxic lymphocyte responses to clinical outcome during cytomegalovirus infection. Cytomegalovirus infection developed in 20 patients; of these 20, 14 had cytomegalovirus-specific cytotoxic lymphocyte responses whereas six did not. Clinical findings (fever, leukopenia, thrombocytopenia, or elevations in serum transaminase levels) were significantly more frequent among patients without responses than among patients with responses (p less than 0.001), and prolonged viremia and complications of infection including superinfection, interstitial pneumonitis, pancreatitis, and death occurred exclusively among patients without responses. Acute allograft dysfunction during infection was experienced by four patients without responses but by only one patient with response (p = 0.02), indicating that the virus-specific cytotoxic response did not result in a renal immunopathologic condition, and may have protected against virus-induced injury to the graft. In seven of nine patients with responses who shed virus, cytotoxic responses occurred within one week of detection of activation of virus shedding. Absence of cytotoxic responses correlated with prior high-dose, intravenous methylprednisolone treatment, and apparently resulted from inhibition of cytotoxic T cell precursors. Immunosuppressive treatment to inhibit graft rejection should be minimized, and methods should be developed that do not inhibit cytomegalovirus-specific cytotoxic T cell responses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322583     DOI: 10.1016/0002-9343(84)90655-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection.

Authors:  J van Zanten; M van der Giessen; L H van der Voort; W J van Son; W van der Bij; T H The
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

2.  Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in suckling mice.

Authors:  P A Offit; K I Dudzik
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

Review 3.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

4.  Cytomegalovirus (CMV) infections in patients receiving CMV-IgG-hyperimmunoglobulin prophylaxis after bone-marrow transplantation.

Authors:  T Schmeiser; W Heit; R Arnold; D Bunjes; M Wiesneth; B Hertenstein; W Hampl; H Heimpel
Journal:  Klin Wochenschr       Date:  1987-10-15

5.  Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual.

Authors:  S Koenig; P Earl; D Powell; G Pantaleo; S Merli; B Moss; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques.

Authors:  A Kaur; M D Daniel; D Hempel; D Lee-Parritz; M S Hirsch; R P Johnson
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 7.  Cytomegalovirus infection in the gastrointestinal tract.

Authors:  R Chetty; D E Roskell
Journal:  J Clin Pathol       Date:  1994-11       Impact factor: 3.411

8.  Sera from patients with the acquired immunodeficiency syndrome inhibit production of interleukin-2 by normal lymphocytes.

Authors:  J P Siegel; J Y Djeu; N I Stocks; H Masur; E P Gelmann; G V Quinnan
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

9.  Rapid degradation of the heavy chain of class I major histocompatibility complex antigens in the endoplasmic reticulum of human cytomegalovirus-infected cells.

Authors:  Y Yamashita; K Shimokata; S Saga; S Mizuno; T Tsurumi; Y Nishiyama
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Interleukin 2 therapy in infectious diseases: rationale and prospects.

Authors:  J P Siegel; A H Rook; J Y Djeu; G V Quinnan
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.